文献速递头颈部肿瘤放疗

甲状腺V40预测鼻咽癌IMRT后原发性甲状腺功能减退

Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-03-14

本研究纳入102例临床甲状腺功能正常的鼻咽癌患者,分析IMRT后原发性甲状腺功能减退(HT)的预测因素。中位随访48.8个月,43.1%患者在放疗后2年内发生HT。多因素分析显示年轻年龄、早期T分期和甲状腺V40是HT的独立预测因素,V40>85%者HT累积发生率显著更高。

要点

  • 甲状腺V40是鼻咽癌IMRT后原发性HT的独立预测因素。
  • V40>85%者HT累积发生率显著高于V40≤85%者(P=.007)。
  • V40≤85%可作为IMRT计划中的甲状腺剂量约束而不影响肿瘤覆盖。

核心结论

  • 甲状腺V40可预测鼻咽癌IMRT后原发性HT,V40≤85%可作为有用的剂量约束。

研究设计与样本

  • 回顾性分析2009年9月至2012年8月纳入的102例临床甲状腺功能正常的鼻咽癌患者,均接受IMRT,随机分配至诱导化疗后同步放化疗或单纯同步放化疗。

主要发现

  • 中位随访48.8个月,102例中44例(43.1%)在放疗后2年内发生HT,中位发生时间36.7个月(范围24.9-49.0个月)。
  • 1年和2年HT累积发生率分别为33%和44.5%。
  • 单因素分析显示年轻年龄、早期T分期、甲状腺最小剂量、V40和V45与HT相关。
  • 多因素分析显示年轻年龄(P=.017)、早期T分期(P=.005)和V40(P=.009)仍具有统计学显著性。
  • V40>85%的患者HT累积发生率显著高于V40≤85%的患者(P=.007)。

关键数值与推荐

  • 甲状腺V40>85%者HT累积发生率显著高于V40≤85%者(P=.007)。
  • V40≤85%可作为IMRT计划中的剂量约束而不影响肿瘤覆盖。

临床怎么用

  • 在鼻咽癌IMRT计划中,可将甲状腺V40限制在≤85%以降低原发性HT风险,同时不牺牲肿瘤覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the various clinical and thyroid dosimetric parameters that could predict the risk of primary hypothyroidism (HT) after intensity modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC) and to determine useful thyroid dose constraints to guide radiation therapy planning. METHODS AND MATERIALS: From September 2009 to August 2012, 102 clinically euthyroid NPC patients were included in this study. All patients were treated with IMRT and randomized to induction chemotherapy followed by concurrent chemo-IMRT or concurrent chemo-IMRT alone. Thyroid function was evaluated by measuring thyroid-stimulating hormone and free thyroxine at each annual follow-up visit. Various clinical and dosimetric parameters (eg, V40 [percentage of thyroid volume receiving >40 Gy]) were obtained. Univariate and multivariate logistic regression analyses were performed to identify predictors of HT. RESULTS: Median follow-up was 48.8 months. Among the 102 patients, 44 (43.1%) developed HT within 2 years after radiation therapy. The median time to HT was 36.7 months (range, 24.9-49.0 months). The 1-year and 2-year cumulative incidence rates of HT were 33% and 44.5%, respectively. Univariate analysis revealed that younger age, early T stage, minimum dose to the thyroid gland, V40, and V45 were associated with HT. On multivariate analysis, younger age (P=.017), early T stage (P=.005), and V40 (P=.009) remained statistically significant. Patients with V40 > 85% had significantly higher cumulative incidence rates of HT than patients with V40 ≤ 85% (P=.007). CONCLUSIONS: Thyroid V40 is predictive of primary HT after IMRT for NPC, and V40 ≤ 85% can be a useful dose constraint to adopt during IMRT planning without compromising tumor coverage.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sommat K, Ong WS, Hussain A, et al. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581397. doi:10.1016/j.ijrobp.2017.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。